Skip to main content
Pharmaceuticals logoLink to Pharmaceuticals
. 2024 Apr 1;17(4):453. doi: 10.3390/ph17040453

Correction: Liu et al. The Discovery of Novel Agents against Staphylococcus aureus by Targeting Sortase A: A Combination of Virtual Screening and Experimental Validation. Pharmaceuticals 2024, 17, 58

Kang Liu 1,, Jiangbo Tong 1,, Xu Liu 2, Dan Liang 1, Fangzhe Ren 1, Nan Jiang 1, Zhenyu Hao 1, Shixin Li 1,*, Qiang Wang 3,*
PMCID: PMC11054560  PMID: 38675504

Error in Table and Figure Description

In the original publication [1], there were mistakes in Table 1 as published. Firstly, the molecular structures of screened compound ID 2 (Naldemedine) and compound ID 4 (Norgestrel) were described incorrectly. Secondly, compound ID 8 (Doxycycline) was inconsistent with the structure in Figure S8. The correct name of compound 8 is Simeprevir. The corrected Table 1, along with corresponding corrections in the Table S1 and Figure S8 descriptions, are provided below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Table 1.

The molecular docking results indicate that the top 12 drugs have binding energies below −9.0 kcal/mol. The positive and negative controls are depicted in the final two lines. The occupied sites correspond to the binding sites of LPXTG, as shown in Figure 1c.

ID Compound Structure Binding Energy (kcal/mol) corrScore Ratio of Occupied Sites
1 Trypan Blue graphic file with name pharmaceuticals-17-00453-i001.jpg −9.6 0 0
2 Naldemedine graphic file with name pharmaceuticals-17-00453-i002.jpg −9.6 0.84 71.4%
3 Lomitapide graphic file with name pharmaceuticals-17-00453-i003.jpg −9.4 0.69 64.3%
4 Norgestrel graphic file with name pharmaceuticals-17-00453-i004.jpg −9.2 0.86 0
5 Triazolam graphic file with name pharmaceuticals-17-00453-i005.jpg −9.1 0.82 50.0%
6 Flourescein graphic file with name pharmaceuticals-17-00453-i006.jpg −9.1 0.82 57.1%
7 Midazolam graphic file with name pharmaceuticals-17-00453-i007.jpg −9.0 0.80 64.3%
8 Simeprevir graphic file with name pharmaceuticals-17-00453-i008.jpg −9.0 0.55 50.0%
9 Alprazolam graphic file with name pharmaceuticals-17-00453-i009.jpg −9.0 0.80 50.0%
10 Telmisartan graphic file with name pharmaceuticals-17-00453-i010.jpg −9.0 0.72 71.4%
11 Nilotinib graphic file with name pharmaceuticals-17-00453-i011.jpg −9.0 0.71 64.3%
12 Azilsartan graphic file with name pharmaceuticals-17-00453-i012.jpg −9.0 0.69 85.7%
Positive control Rosmarinic acid graphic file with name pharmaceuticals-17-00453-i013.jpg −7.6 0.39 64.3%
Negative control 2,3-Bis(4-methoxyphenyl)propanenitrile graphic file with name pharmaceuticals-17-00453-i014.jpg −6.2 0.18 35.7%

Table S1.

Binding sites of 12 screened drugs and two controls. Residues marked in red are the functional sites of SrtA, as indicated in Figure 1c.

ID Compound Binding Sites
1 Trypan Blue Thr121, Phe122, Ile123, Thr131, Lys134, Asp185, Asp186, Tyr187, Gly192, Val193, Trp194, Lys198
2 Naldemedine Pro91, Ala92, Leu97, Ala104, Glu105, Glu106, Ala118, Gly119, His120, Val166, Val168, Leu169, Ile182, Cys184, Trp194, Arg197
3 Lomitapide Pro91, Ala92, Thr93, Leu97, Ala104, Glu105, Glu106, His120, Lys162, Asp165, Val166, Val168, Leu169, Ile182, Arg197
4 Norgestrel Thr121, Ile123, Asp185, Asp186, Phe122, Trp194, Tyr187
5 Triazolam Ala92, Ala104, His120, Val168, Leu169, Ile182, Cys184, Arg197
6 Flourescein Ala104, Ala118, Val161, Lys162, Thr164, Asp165, Val168, Leu169, Ile182, Arg197
7 Midazolam Ala92, Ala104, His120, Thr164, Asp165, Val168, Leu169, Ile182, Cys184, Arg197
8 Simeprevir Pro91, Ala92, Thr93, Glu95, Ala104, Glu105, Ala118, Asp165, Val166, Leu169, Ile182, Arg197
9 Alprazolam Ala92, Ala104, His120, Val168, Leu169, Ile182, Cys184, Arg197
10 Telmisartan Pro91, Ala92, Thr93, Leu97, Ala104, Glu105, Glu106, Ala118, His120, Lys162, Thr164, Asp165, Val166, Val168, Leu169, Arg197, Ile199
11 Nilotinib Pro91, Thr93, Ala104, Glu105, Glu106, Asn107, Ala118, Gly119, Lys162, Thr164, Asp165, Val168, Ile182, Arg197, Ile199
12 Azilsartan Pro91, Ala92, Thr93, Leu97, Ala104, His120, Lys162, Pro163, Thr164, Asp165, Val166, Val168, Val169, Ile182, Cys184, Arg197, Ile199
Positive
control
Rosmarinic acid Leu97, Ala104, Ala118, Gly119, His120, Thr121, Val166, Val168, Leu169, Ile182, Ile183, Cys184, Trp194, Arg197
Negative
control
2,3-Bis(4-methoxyphenyl)propanenitrile Ala92, Leu97, Ala104, Pro163, Val166, Val168, Ieu169

Figure S8.

Figure S8

Analysis of the binding pose of Simeprevir with SrtA. (a) The structure of the complex. Three-dimensional (b) and two-dimensional (c) interaction diagrams of the binding pose of Simeprevir with SrtA.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Reference

  • 1.Liu K., Tong J., Liu X., Liang D., Ren F., Jiang N., Hao Z., Li S., Wang Q. The Discovery of Novel Agents against Staphylococcus aureus by Targeting Sortase A: A Combination of Virtual Screening and Experimental Validation. Pharmaceuticals. 2024;17:58. doi: 10.3390/ph17010058. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Pharmaceuticals are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES